Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)

Hans-Georg Schnürch; Sven Ackermann; Celine D. Alt-Radtke; Lukas Angleitner; Jana Barinoff; Matthias W. Beckmann; Carsten Böing; Christian Dannecker; Tanja Fehm; Rüdiger Gaase; Paul Gass; Marion Gebhardt; Friederike Gieseking; Andreas Günthert; Carolin C. Hack; Peer Hantschmann; Lars Christian Horn; Martin C. Koch; Anne Letsch; Peter Mallmann; Bernhard Mangold; Simone Marnitz; Grit Mehlhorn; Kerstin Paradies; Michael J. Reinhardt; Reina Tholen; Uwe Torsten; Wolfgang Weikel; Linn Wölber; Monika Hampl

doi:10.1055/a-0919-4959

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2019; 79(10): 1060-1078
DOI: 10.1055/a-0919-4959

GebFra Science

Guideline/Leitlinie

Georg Thieme Verlag KG Stuttgart · New York

Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)

Article in several languages: English | deutsch

Hans-Georg Schnürch

¹Ehem. Frauenklinik Lukaskrankenhaus, Neuss, Germany

,

Sven Ackermann

²Frauenklinik, Klinikum Darmstadt, Darmstadt, Germany

,

Celine D. Alt-Radtke

³Institut für Diagnostische und Interventionelle Radiologie, Universität Düsseldorf, Düsseldorf, Germany

,

Lukas Angleitner

⁴Frauenklinik, Kepler-Universitätsklinikum Linz, Linz, Austria

,

Jana Barinoff

⁵St.-Gertrauden-Krankenhaus GmbH Berlin, Berlin, Germany

,

Matthias W. Beckmann

⁶Frauenklinik, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen–Nürnberg; Comprehensive Cancer Center (CCC) Erlangen-EMN, Erlangen, Germany

,

Carsten Böing

⁷Katholisches Klinikum Oberhausen, Frauenklinik St. Clemens-Hospital, Oberhausen, Germany

,

Christian Dannecker

⁸Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität München, Campus Großhadern, München, Germany

,

Tanja Fehm

⁹Klinik für Frauenheilkunde und Geburtshilfe, Universität Düsseldorf, Düsseldorf, Germany

,

Rüdiger Gaase

¹⁰Gemeinschaftspraxis für Frauenheilkunde Gaase+Hugger, Worms, Germany

,

Paul Gass

⁶Frauenklinik, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen–Nürnberg; Comprehensive Cancer Center (CCC) Erlangen-EMN, Erlangen, Germany

,

Marion Gebhardt

¹¹Frauenselbsthilfe nach Krebs, Erlangen, Germany

,

Friederike Gieseking

¹²Dysplasiesprechstunde/Gynäkologisches Laserzentrum in der Frauenarztpraxis Heussweg, Hamburg, Germany

,

Andreas Günthert

¹³Gyn-Zentrum für Frauengesundheit, Luzern, Switzerland

,

Carolin C. Hack

⁶Frauenklinik, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen–Nürnberg; Comprehensive Cancer Center (CCC) Erlangen-EMN, Erlangen, Germany

,

Peer Hantschmann

¹⁴Abteilung Gynäkologie und Geburtshilfe, Kreiskliniken Altötting – Burghausen, Altötting, Germany

,

Lars Christian Horn

¹⁵Institut für Pathologie, Universitätsklinikums Leipzig, Leipzig, Germany

,

Martin C. Koch

⁶Frauenklinik, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen–Nürnberg; Comprehensive Cancer Center (CCC) Erlangen-EMN, Erlangen, Germany

,

Anne Letsch

¹⁶Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité Berlin, Berlin, Germany

,

Peter Mallmann

¹⁷Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität Köln, Köln, Germany

,

Bernhard Mangold

¹⁸Zyto-Labor Ludwigsburg, Ludwigsburg, Germany

,

Simone Marnitz

¹⁹Klinik für Radioonkologie, CyberKnife- und Strahlentherapie, Uniklinik Köln, Köln, Germany

,

Grit Mehlhorn

²⁰Frauenarztpraxis Erlangen, Erlangen, Germany

,

Kerstin Paradies

²¹Konferenz Onkologischer Kranken- und Kinderkrankenpflege, Berlin, Germany

,

Michael J. Reinhardt

²²Klinik für Nuklearmedizin, Pius-Hospital Oldenburg, Oldenburg, Germany

,

Reina Tholen

²³Deutscher Verband für Physiotherapie, Köln, Germany

,

Uwe Torsten

²⁴Klinik für Gynäkologie und Zentrum für Beckenbodenerkrankungen, Vivantes Klinikum Neukölln, Berlin, Germany

,

Wolfgang Weikel

²⁵Klinik für Gynäkologie und gynäkologische Onkologie, Universitätsfrauenklinik Mainz, Mainz, Germany

,

Linn Wölber

²⁶Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

,

Monika Hampl

⁹Klinik für Frauenheilkunde und Geburtshilfe, Universität Düsseldorf, Düsseldorf, Germany

› Author Affiliations

Abstract

Purpose This is an official guideline, published and coordinated by the Gynecological Oncology Working Group (AGO) of the German Cancer Society (DKG) and the German Society for Gynecology and Obstetrics (DGGG). Vaginal cancers are rare tumors, which is why there is very little evidence on these tumors. Knowledge about the optimal clinical management is limited. This first German S2k guideline on vaginal cancer has aimed to compile the most current expert knowledge and offer new recommendations on the appropriate treatment as well as providing pointers about individually adapted therapies with lower morbidity rates than were previously generally available. The purpose of this guideline is also to set up a register to record data on treatment data and the course of disease as a means of obtaining evidence in future.

Methods The present S2k guideline was developed by members of the Vulvar und Vaginal Tumors Commission of the AGO in an independently moderated, structured, formal consensus process and the contents were agreed with the mandate holders of the participating scientific societies and organizations.

Recommendations To optimize the daily care of patients with vaginal cancer: 1. Monitor the spread pattern; 2. Follow the step-by-step diagnostic workup based on initial stage at detection; 3. As part of individualized clinical therapeutic management of vaginal cancer, follow the sentinel lymph node protocol described here, where possible; 4. Participate in the register study on vaginal cancer.

Key words

vaginal cancer - VaIN - sentinel lymph node biopsy

Full Text

References

References/Literatur
1 Schubert-Fritschle G, Schlesinger-Raab A, Engel J. Malignome der Vulva und Vagina. In: Dannecker C, Kolben M, Kürzl R. Hrsg. Manuale Tumorzentrum München. 2. Aufl.. München: Zuckschwerdt Verlag; 2011
2 Lilic V, Lilic G, Filipovic S. et al. Primary carcinoma of the vagina. J BUON 2010; 15: 241-247
3 Melnick S, Cole P, Anderson D. et al. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med 1987; 316: 514-516
4 Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ. eds. SEER Survival Monograph: Cancer Survival among Adults: U.S. SEER Program, 1988 – 2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD: NIH. 2007
5 Madsen BS, Jensen HL, van den Brule AJ. et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina–population-based case-control study in Denmark. Int J Cancer 2008; 122: 2827-2834
6 Henson D, Tarone R. An epidemiologic study of cancer of the cervix, vagina, and vulva based on the Third National Cancer Survey in the United States. Am J Obstet Gynecol 1977; 129: 525-532
7 Aho M, Vesterinen E, Meyer B. et al. Natural history of vaginal intraepithelial neoplasia. Cancer 1991; 68: 195-197
8 Gadducci A, Fabrini MG, Lanfredini N. et al. Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. Crit Rev Oncol Hematol 2015; 93: 211-224
9 Strander B, Andersson-Ellstrom A, Milsom I. et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007; 335: 1077
10 Horn LC, Schierle K. Pathologie der Präkanzerosen und der Karzinome von Vulva und Vagina sowie morphologische Prognosefaktoren. Onkologe 2009; 15: 15-27
11 Ferenzcy AS, Colgan TJ, Herrington CS, Hirschowitz L, Löning T, Park KJ, Stoler M, Wells M, Wilbur DC, Wright T. Epithelial Tumors of the Vagina. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH. eds. WHO Classification of Tumours of the female reproductive Tract. Lyon: IARC Press; 2014: 210-217
12 Horn LC, Schierle K, Schmidt D. et al. [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed mullerian tumors. Facts and background]. Pathologe 2011; 32: 239-243
13 Darragh TM, Colgan TJ, Thomas Cox J. et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32: 76-115
14 Wittekind C. TNM-Klassifikation maligner Tumoren. 8th ed. Weinheim: Wiley-VHC; 2017: 213-215
15 Adams TS, Cuello MA. Cancer of the vagina. Int J Gynaecol Obstet 2018; 143 (Suppl. 02) 14-21
16 Wu X, Matanoski G, Chen VW. et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer 2008; 113: 2873-2882
17 Kurman RJ, Ronnett BM, Sherman ME, Wilkinson EJ. Tumors of the Vagina. Tumors of the Cervix, Vagina and Vulva. In: Kurman RJ, Ronnett BM, Sherman ME, Wilkinson EJ. eds. AFIP Atlas of Tumor Pathology, Series 4. Silver Spring: ARP Press; 2010: 255-291
18 Wilkinson EJ, Rico MJ, Pierson KK. Microinvasive carcinoma of the vulva. Int J Gynecol Pathol 1982; 1: 29-39
19 Crum CP, Herrington CS, McCluggage WG, Regauer S, Wilkinson EJ. Epithelial Tumors of the Vulva. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH. eds. WHO Classification of Tumours of the female reproductive Tract. Lynon: IARC Press; 2014: 233-242
20 Hermanek P, Hutter RV, Sobin LH. et al. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86: 2668-2673
21 Wittekind C, Compton C, Brirley J, Sobin L. TNM Supplement: a Commentary on Uniform Use. London: Wiley-Blackwell; 2012
22 American Joint Committee on Cancer. Vagina. In: Amin MB, Edge S, Greene F. et al., eds. AJCC Cancer Staging Manual. 8th ed. New York: Spinger; 2017: 641-647
23 Luo LM, Huang HF, Pan LY. et al. [Clinical analysis of 42 cases of primary malignant tumor in vagina]. Zhonghua Fu Chan Ke Za Zhi 2008; 43: 923-927
24 Stock RG, Chen AS, Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 1995; 56: 45-52
25 Manetta A, Gutrecht EL, Berman ML. et al. Primary invasive carcinoma of the vagina. Obstet Gynecol 1990; 76: 639-642
26 Tjalma WA, Monaghan JM, de Barros Lopes A. et al. The role of surgery in invasive squamous carcinoma of the vagina. Gynecol Oncol 2001; 81: 360-365
27 Frank SJ, Jhingran A, Levenback C. et al. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005; 62: 138-147
28 de Crevoisier R, Sanfilippo N, Gerbaulet A. et al. Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiother Oncol 2007; 85: 362-370
29 Greenwalt JC, Amdur RJ, Morris CG. et al. Outcomes of Definitive Radiation Therapy for Primary Vaginal Carcinoma. Am J Clin Oncol 2015; 38: 583-587
30 Lian J, Dundas G, Carlone M. et al. Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. Gynecol Oncol 2008; 111: 298-306
31 Jang WI, Wu HG, Ha SW. et al. Definitive radiotherapy for treatment of primary vaginal cancer: effectiveness and prognostic factors. Int J Gynecol Cancer 2012; 22: 521-527
32 Smith GL, Jiang J, Giordano SH. et al. Trends in the Quality of Treatment for Patients With Intact Cervical Cancer in the United States, 1999 Through 2011. Int J Radiat Oncol 2015; 92: 260-267
33 Showalter TN, Camacho F, Cantrell LA. et al. Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia. Medicine (Baltimore) 2016; 95: e2913
34 Lin JF, Berger JL, Krivak TC. et al. Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol 2014; 132: 416-422
35 Bakker RM, ter Kuile MM, Vermeer WM. et al. Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method. Int J Gynecol Cancer 2014; 24: 1499-1506
36 Bakker RM, Mens JW, de Groot HE. et al. A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer. Support Care Cancer 2016;
37 Bakker RM, Vermeer WM, Creutzberg CL. et al. Qualitative accounts of patientsʼ determinants of vaginal dilator use after pelvic radiotherapy. J Sex Med 2015; 12: 764-773
38 Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016; (08) CD001500
39 Perri T, Ben-Baruch G, Davidson T. et al. Use of Titanium Spiral Tacks for Long-term Oophoropexy Before Pelvic Irradiation. Int J Gynecol Cancer 2014; 24: 1133-1136
40 Han SS, Kim YH, Lee SH. et al. Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuvant pelvic irradiation. J Obstet Gynaecol Res 2011; 37: 825-829
41 Morice P, Castaigne D, Haie-Meder C. et al. Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes. Fertil Steril 1998; 70: 956-960
42 Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7: 535-543
43 Ghadjar P, Budach V, Kohler C. et al. Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. Radiat Oncol 2015; 10: 50
44 DGGG; DGU, BGRM. Fertility preservation for patients with malignant disease. Guideline of the DGGG, DRU and BGRM (S2k – Level, AWMF Registry No. 015/082, November 2017). 2017. Online: http://www.ammf.org/leitlinien/detail/II/015-082.html last access: 15.02.2018
45 Salani R, Backes FJ, Fung MF. et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204: 466-478
46 Dannecker C, Strand V, Hegewisch-Becker S. Nachsorge beim Vulva- und Vaginalkarzinom. Der Onkologe 2014; 20: 355-357
47 Oonk MH, de Hullu JA, Hollema H. et al. The value of routine follow-up in patients treated for carcinoma of the vulva. Cancer 2003; 98: 2624-2629
48 Gardner CS, Sunil J, Klopp AH. et al. Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. Br J Radiol 2015; 88: 20150033
49 Gunderson CC, Nugent EK, Yunker AC. et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. J Low Genit Tract Dis 2013; 17: 409-413